{"Title": "Prioritizing precision medicine for prostate cancer", "Year": 2015, "Source": "Ann. Oncol.", "Volume": "26", "Issue": 6, "Art.No": null, "PageStart": 1041, "PageEnd": 1042, "CitedBy": 6, "DOI": "10.1093/annonc/mdv179", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84938062292&origin=inward", "Abstract": null, "AuthorKeywords": null, "IndexKeywords": ["Biomarkers, Tumor", "Gene Expression Profiling", "Humans", "Male", "Prostatic Neoplasms"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 1, "EID": "2-s2.0-84938062292", "SubjectAreas": [["Hematology", "MEDI", "2720"], ["Oncology", "MEDI", "2730"]], "AuthorData": {"9740870900": {"Name": "Attard G.", "AuthorID": "9740870900", "AffiliationID": "60010337, 60017166", "AffiliationName": "The Institute of Cancer Research, Royal Marsden NHS Foundation Trust"}, "36024985600": {"Name": "Beltran H.", "AuthorID": "36024985600", "AffiliationID": "60007997", "AffiliationName": "Division of Medicine, Weill Cornell Medical College"}}}